Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H E Wander

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Onkologie|December 1, 1984
[Panmyelopathy induced by aminoglutethimide. Report of a clinical case]H E Wander
Onkologie|August 1, 1982
[Vindesine and adriamycin in the therapy of metastatic breast cancer]H E Wander, G A Nagel
Onkologie|August 1, 1986
[Responsible risks in the choice of palliative chemotherapy]G A Nagel, H E Wander
Deutsche Medizinische Wochenschrift (1946)|January 13, 1984
[Importance of prolactin determination in metastatic breast cancer]H E Wander, W Holtkamp, G A Nagel
Onkologie|August 1, 1982
[Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]H E Wander, G A Nagel, H C Blossey
Cancer Research|August 1, 1982
Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancerG A Nagel, H E Wander, H C Blossey
European Journal of Cancer & Clinical Oncology|November 1, 1986
Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancerH E Wander, H C Blossey, G A Nagel
Schweizerische Medizinische Wochenschrift|December 12, 1981
[Hyperprolactinemia in metastasizing breast cancer]G A Nagel, H E Wander, H C Blossey
Klinische Wochenschrift|June 1, 1983
[High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles]H E Wander, C Blossey, J Köbberling, et al.
Klinische Wochenschrift|April 1, 1987
Intensive short-term chemotherapy in patients with advanced breast cancerH E Wander, G A Nagel, H Luig, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Onkologie|December 1, 1984
[Panmyelopathy induced by aminoglutethimide. Report of a clinical case]H E Wander
Onkologie|August 1, 1982
[Vindesine and adriamycin in the therapy of metastatic breast cancer]H E Wander, G A Nagel
Onkologie|August 1, 1986
[Responsible risks in the choice of palliative chemotherapy]G A Nagel, H E Wander
Deutsche Medizinische Wochenschrift (1946)|January 13, 1984
[Importance of prolactin determination in metastatic breast cancer]H E Wander, W Holtkamp, G A Nagel
Onkologie|August 1, 1982
[Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]H E Wander, G A Nagel, H C Blossey
Cancer Research|August 1, 1982
Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancerG A Nagel, H E Wander, H C Blossey
European Journal of Cancer & Clinical Oncology|November 1, 1986
Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancerH E Wander, H C Blossey, G A Nagel
Schweizerische Medizinische Wochenschrift|December 12, 1981
[Hyperprolactinemia in metastasizing breast cancer]G A Nagel, H E Wander, H C Blossey
Klinische Wochenschrift|June 1, 1983
[High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles]H E Wander, C Blossey, J Köbberling, et al.
Klinische Wochenschrift|April 1, 1987
Intensive short-term chemotherapy in patients with advanced breast cancerH E Wander, G A Nagel, H Luig, et al.
Pageof 4